Total Payments
$114,610
2024 Payments
$12,723
Companies
19
Transactions
204
Medicare Patients
10,178
Medicare Billing
$1.1M
Payment Breakdown by Category
Consulting$112,250 (97.9%)
Food & Beverage$2,282 (2.0%)
Education$77.88 (0.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $112,250 | 94 | 97.9% |
| Food and Beverage | $2,282 | 99 | 2.0% |
| Education | $77.88 | 11 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Abbott Laboratories | $112,273 | 95 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $505.27 | 25 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $486.87 | 22 | $0 (2022) |
| Amgen Inc. | $252.92 | 10 | $0 (2024) |
| Kiniksa Pharmaceuticals International, plc | $230.01 | 10 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $195.18 | 16 | $0 (2019) |
| PFIZER INC. | $116.50 | 4 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $102.84 | 4 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $91.72 | 4 | $0 (2018) |
| Novo Nordisk Inc | $91.67 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,723 | 27 | Abbott Laboratories ($12,250) |
| 2023 | $250.27 | 11 | Kiniksa Pharmaceuticals, Ltd. ($90.71) |
| 2022 | $8,358 | 23 | Abbott Laboratories ($8,000) |
| 2021 | $12,236 | 22 | Abbott Laboratories ($12,000) |
| 2020 | $29,096 | 33 | Abbott Laboratories ($29,000) |
| 2019 | $18,396 | 44 | Abbott Laboratories ($18,000) |
| 2018 | $18,237 | 20 | Abbott Laboratories ($18,000) |
| 2017 | $15,315 | 24 | Abbott Laboratories ($15,000) |
All Payment Transactions
204 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Abbott Laboratories | XIENCE V (Device) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: Vascular | ||||||
| 11/21/2024 | Abbott Laboratories | XIENCE V (Device) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Vascular | ||||||
| 11/20/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $16.61 | General |
| Category: Cardiovascular | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $26.79 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/13/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $33.54 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/07/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $26.49 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 11/01/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $30.16 | General |
| Category: Cardiovascular | ||||||
| 10/23/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $18.47 | General |
| Category: Cardiology | ||||||
| 10/17/2024 | Abbott Laboratories | XIENCE V (Device) | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| Category: Vascular | ||||||
| 10/16/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $25.77 | General |
| Category: Not Applicable | ||||||
| 09/25/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $40.00 | General |
| Category: Cardiovascular | ||||||
| 09/11/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $33.38 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/08/2024 | Abbott Laboratories | XIENCE V (Device) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Vascular | ||||||
| 08/01/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $27.50 | General |
| Category: Not Applicable | ||||||
| 07/31/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $22.35 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/17/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $25.35 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 07/10/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $16.07 | General |
| Category: Cardiovascular | ||||||
| 06/26/2024 | Abbott Laboratories | XIENCE V (Device) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Vascular | ||||||
| 06/18/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $24.53 | General |
| Category: Obesity | ||||||
| 06/07/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $22.48 | General |
| Category: Not Applicable | ||||||
| 05/30/2024 | Abbott Laboratories | XIENCE V (Device) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Vascular | ||||||
| 04/25/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $20.73 | General |
| Category: Not Applicable | ||||||
| 04/24/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $18.74 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/17/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $24.27 | General |
| Category: Diabetes | ||||||
| 03/27/2024 | Abbott Laboratories | XIENCE V (Device) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: Vascular | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 2,617 | 3,451 | $1.6M | $256,272 |
| 2022 | 15 | 2,640 | 3,615 | $1.6M | $273,800 |
| 2021 | 14 | 2,615 | 3,576 | $1.6M | $306,908 |
| 2020 | 18 | 2,306 | 3,032 | $1.3M | $231,708 |
Total Patients
10,178
Total Services
13,674
Medicare Billing
$1.1M
Procedure Codes
72
All Medicare Procedures & Services
72 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 721 | 1,037 | $549,610 | $110,633 | 20.1% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 284 | 289 | $511,530 | $48,951 | 9.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 101 | 140 | $103,600 | $21,309 | 20.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 859 | 1,233 | $110,970 | $15,007 | 13.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 33 | 109 | $49,390 | $11,720 | 23.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 87 | 87 | $57,420 | $11,035 | 19.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 184 | 192 | $75,910 | $10,946 | 14.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 127 | 141 | $53,580 | $10,143 | 18.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 24 | 24 | $20,020 | $4,800 | 24.0% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 20 | 20 | $27,200 | $4,270 | 15.7% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 20 | 20 | $11,600 | $1,884 | 16.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 11 | $5,940 | $1,311 | 22.1% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 17 | 17 | $6,970 | $1,155 | 16.6% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Office | 2023 | 20 | 20 | $6,200 | $954.00 | 15.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 13 | $3,770 | $888.49 | 23.6% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Office | 2023 | 20 | 20 | $8,350 | $445.80 | 5.3% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 16 | 16 | $2,500 | $353.44 | 14.1% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Facility | 2023 | 20 | 20 | $2,000 | $313.00 | 15.7% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Facility | 2023 | 31 | 31 | $620.00 | $82.77 | 13.3% |
| 93321 | Ultrasound of heart blood flow, valves and chambers, follow-up | Facility | 2023 | 11 | 11 | $440.00 | $70.84 | 16.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 653 | 967 | $511,551 | $101,136 | 19.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 248 | 249 | $425,120 | $42,231 | 9.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 124 | 172 | $127,280 | $26,244 | 20.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 60 | 215 | $83,615 | $19,737 | 23.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 830 | 1,217 | $109,477 | $14,705 | 13.4% |
About Dr. David Engel, M.D
Dr. David Engel, M.D is a Cardiovascular Disease healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1043397144.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Engel, M.D has received a total of $114,610 in payments from pharmaceutical and medical device companies, with $12,723 received in 2024. These payments were reported across 204 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($112,250).
As a Medicare-enrolled provider, Engel has provided services to 10,178 Medicare beneficiaries, totaling 13,674 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 72 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location New York, NY
- Active Since 11/01/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1043397144
Products in Payments
- Xience cornary stent systems (Device) $31,500
- Xience V coronary stent system (Device) $28,000
- XIENCE V (Device) $18,250
- Absorb (Device) $17,000
- ABSORB (Device) $7,000
- Tricuspid Valve Repair System (Device) $5,500
- Absorb GT1 (Device) $3,000
- ABSORB GT1 (Device) $1,000
- PORTICO (Device) $1,000
- XARELTO (Drug) $486.87
- ENTRESTO (Drug) $286.73
- Arcalyst (Drug) $230.01
- LEQVIO (Drug) $218.54
- Repatha (Biological) $208.69
- ELIQUIS (Drug) $133.11
- JARDIANCE (Drug) $107.56
- PRADAXA (Drug) $87.62
- CAMZYOS (Drug) $86.23
- Ozempic (Drug) $67.14
- PRALUENT (Drug) $66.97
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in New York
Dr. Roger Hajjar, Md, MD
Cardiovascular Disease — Payments: $5.2M
Cardiovascular Disease $5.2M
Dr. Jacob Koruth, M.d, M.D
Cardiovascular Disease — Payments: $3.2M
Cardiovascular Disease $3.2M
Dr. Martin Leon, M.d, M.D
Cardiovascular Disease — Payments: $2.7M
Cardiovascular Disease $2.7M
Dr. Gregg Stone, M.d, M.D
Cardiovascular Disease — Payments: $2.2M
Cardiovascular Disease $2.2M
Adam Rosenbluth, Md, MD
Cardiovascular Disease — Payments: $1.5M
Cardiovascular Disease $1.5M
Dr. Deepak Bhatt, Md, MD
Cardiovascular Disease — Payments: $1.4M
Cardiovascular Disease $1.4M